KRAS and non-small cell lung carcinoma: In the first study, a large multicenter series from France, comprising 384 never smokers with NSCLC (adenocarcinoma histology– 85%), Couraud et al. [6] reported ALK rearrangement and EGFR, KRAS, BRAF, ERBB2 and PIK3CA mutation in 13%, 43%, 7%, 5%, 4% and 2% of tested patients, respectively, using different genotyping methods in overall 75 participating centers.